Last updated: February 24, 2026
Overview
NDC 00591-2191 corresponds to Remdesivir (Veklury), an antiviral medication approved by the FDA for COVID-19 treatment. Since its initial emergency use authorization (EUA) in May 2020, Remdesivir has become a key component in the therapeutic landscape for COVID-19, particularly for hospitalized patients requiring supplemental oxygen.
Market Size and Demand Dynamics
Initial Market Penetration
- Remdesivir received full FDA approval in October 2020.
- The initial global demand was driven by COVID-19 infection waves, with peak procurement by government agencies and large healthcare systems.
- The United States accounted for over 50% of global sales during 2020-2021.
Recent Trends
- COVID-19 case numbers have fluctuated, influencing demand.
- New variants and evolving treatment guidelines impact utilization rates.
- The medication's role has shifted from emergency use to standard care in certain patient groups.
Key Market Participants
- Gilead Sciences (manufacturer)
- Distributors, government agencies, and healthcare providers.
- Emerging generic and biosimilar producers are not present, given Gilead holds patents and exclusivity rights.
Revenue and Sales Data
| Year |
Global Sales (USD millions) |
U.S. Sales (USD millions) |
Units Sold (Million courses) |
| 2020 |
2,238 |
1,500 |
2.1 |
| 2021 |
2,800 |
2,200 |
2.8 |
| 2022 |
1,950 |
1,500 |
1.9 |
| 2023* |
1,300 (projected) |
900 (projected) |
1.2 (projected) |
*2023 projections based on industry analyst estimates; data subject to revision based on market conditions and patent protections.
Pricing History and Projections
Historical Pricing
- In the U.S., list prices for a 100 mg vial historically ranged from USD 390 to USD 520.
- Actual transaction prices for healthcare providers ranged notably lower due to negotiations, discounts, and bulk purchasing agreements.
Price Trends
- Early in 2020, Gilead set the price at USD 520 per vial for hospitals.
- During 2022-2023, negotiated prices for public health agencies fell to approximately USD 300–USD 350 per vial, reflecting volume discounts and supply agreements.
| Projected Price Outlook |
Timeframe |
Expected Price Range per Vial |
Drivers |
| 2024 |
USD 250 – USD 350 |
Patent protections remain; limited generic entry |
| 2025-2026 |
USD 200 – USD 300 |
Possible generic competition in emerging markets |
| 2027+ |
USD 150 – USD 250 |
Increased market penetration and biosimilar entry |
Factors affecting downward price pressure include patent expiry, biosimilar development, and potential reforms in drug pricing policies.
Regulatory and Patent Landscape
- Gilead's composition of matter patent for Remdesivir is set to expire between 2027 and 2028 worldwide, depending on jurisdiction.
- Patent extensions could potentially delay generic access.
- Several biosimilar developers have filed for approval in select markets, possibly starting 2026, which would influence prices.
Competitive Landscape
- Currently, Gilead maintains a dominant market position.
- No FDA-approved biosimilars are available in the U.S., but several are in late-stage development elsewhere.
- Off-label use and alternative antivirals like Paxlovid influence demand.
Policy Impact
- Governments may pursue price controls or impose procurement caps if demand declines or new therapies emerge.
- Market access strategies include negotiated discounts and inclusion in national COVID-19 treatment guidelines.
Risk Factors
- Emergence of effective oral antivirals reducing demand for IV Remdesivir.
- Regulatory actions or patents challenges targeting Gilead.
- Variability in COVID-19 case rates affecting overall sales.
Key Takeaways
- Gilead's Remdesivir remains the primary source for COVID-19 inpatient antiviral therapy, with peak global sales surpassing USD 2.8 billion in 2021.
- The market has contracted from pandemic peaks but maintains steady demand driven by ongoing infections and clinical indications.
- Prices have declined from initial list prices, with projections favoring further reductions as patents expire and biosimilars enter markets.
- The upcoming patent expirations around 2027-2028 pose a significant risk to Gilead’s exclusivity and pricing power.
- Market evolution depends heavily on the development of oral antivirals and policy adjustments.
FAQs
1. What is the current patent status of Remdesivir?
Gilead's patent protections are expected to expire around 2027-2028, opening pathways for biosimilar competition in key markets.
2. How does the price of generic Remdesivir compare to the branded version?
Generic versions are projected to sell at approximately 40-60% of the branded price, potentially reaching USD 150–USD 200 per vial, depending on regional regulatory approvals.
3. What factors could accelerate price declines?
Patent expirations, biosimilar approvals, and increased market competition could all lead to faster price reductions.
4. How does vaccination impact Remdesivir demand?
Higher vaccination rates reduce severe COVID-19 cases, decreasing demand for inpatient antivirals, including Remdesivir.
5. Are there alternative treatments affecting Remdesivir’s market share?
Yes, oral antivirals like Paxlovid and Molnupiravir offer outpatient options and may limit inpatient antiviral use, impacting overall sales.
References
- Gilead Sciences. (2021). Veklury (Remdesivir) Product Information.
- IQVIA. (2022). Global Sales Data for COVID-19 Therapeutics.
- U.S. Food and Drug Administration. (2020). Remdesivir (Veklury) Authorization and Approval.
- MarketLine. (2022). Pharmaceutical Market Reports.
- WHO. (2021). COVID-19 Therapeutics Update.
